BioCentury | Nov 12, 2020
Finance

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

GV leads $80M series B for COVID antibody play AdagioAdagio Therapeutics Inc. raised $80 million in a series B round led by GV, with backing from existing investors Polaris Partners, Mithril Capital, Fidelity Management &...
BioCentury | Nov 30, 2017
Translation in Brief

Toroids disable TORC

A Nature study from a University of Geneva team has shown that the yeast homolog of mTORC1 forms large aggregates that block the complex’s catalytic site, highlighting an approach for specific inhibition of the complex...
BioCentury | Mar 31, 2016
Product R&D

Stalking Ebola

While the spotlight has moved away from Ebola, companies and academics are still pushing to understand more about the virus and make new therapeutics, in anticipation of the next outbreak. For scientists, the legacy of...
BioCentury | Oct 19, 1998
Emerging Company Profile

ProtoMed Inc.

ProtoMed Inc. Del Mar, Calif. Technology: Bowman-Birk Inhibitors Disease focus: Gastroenterology and oncology Clinical status: Phase Iia Founded: 1996 by Mahendra Shah and Ann Kennedy Corporate partners: Central Soya University collaborators: University of Pennsylvania Number...
BioCentury | Oct 19, 1998
Emerging Company Profile

ProtoMed: Drugs from soybeans

...Drugs from soybeans Having watched the "early commercialization" strategies at a variety of biotech companies, ProtoMed Inc....
...over a product on the market that isn't currently being promoted. On the internal front, ProtoMed...
...showed a statistically significant reduction in lesion size at the second and third dose levels. ProtoMed...
BioCentury | Aug 10, 1998
Company News

ProtoMed other research news

...ulcerative colitis. The company also plans to test the effects of BBIC in Crohn's disease. ProtoMed Inc....
BioCentury | Jul 6, 1998
Company News

ProtoMed management update

ProtoMed Inc., Del Mar, Calif. Business: Autoimmune/Inflammation, Cancer Hired: Louis Scotti as president and director, formerly head of licensing activities for Ligand Pharmaceuticals Inc. WIR Staff autoimmune cancer Inflammation...
BioCentury | Apr 27, 1998
Company News

BBI Pharmaceuticals Inc. cancer news

...BBI changed its name to ProtoMed Inc. The company develops serine protease inhibitors derived from soybeans. BBI...
Items per page:
1 - 8 of 8
BioCentury | Nov 12, 2020
Finance

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

GV leads $80M series B for COVID antibody play AdagioAdagio Therapeutics Inc. raised $80 million in a series B round led by GV, with backing from existing investors Polaris Partners, Mithril Capital, Fidelity Management &...
BioCentury | Nov 30, 2017
Translation in Brief

Toroids disable TORC

A Nature study from a University of Geneva team has shown that the yeast homolog of mTORC1 forms large aggregates that block the complex’s catalytic site, highlighting an approach for specific inhibition of the complex...
BioCentury | Mar 31, 2016
Product R&D

Stalking Ebola

While the spotlight has moved away from Ebola, companies and academics are still pushing to understand more about the virus and make new therapeutics, in anticipation of the next outbreak. For scientists, the legacy of...
BioCentury | Oct 19, 1998
Emerging Company Profile

ProtoMed Inc.

ProtoMed Inc. Del Mar, Calif. Technology: Bowman-Birk Inhibitors Disease focus: Gastroenterology and oncology Clinical status: Phase Iia Founded: 1996 by Mahendra Shah and Ann Kennedy Corporate partners: Central Soya University collaborators: University of Pennsylvania Number...
BioCentury | Oct 19, 1998
Emerging Company Profile

ProtoMed: Drugs from soybeans

...Drugs from soybeans Having watched the "early commercialization" strategies at a variety of biotech companies, ProtoMed Inc....
...over a product on the market that isn't currently being promoted. On the internal front, ProtoMed...
...showed a statistically significant reduction in lesion size at the second and third dose levels. ProtoMed...
BioCentury | Aug 10, 1998
Company News

ProtoMed other research news

...ulcerative colitis. The company also plans to test the effects of BBIC in Crohn's disease. ProtoMed Inc....
BioCentury | Jul 6, 1998
Company News

ProtoMed management update

ProtoMed Inc., Del Mar, Calif. Business: Autoimmune/Inflammation, Cancer Hired: Louis Scotti as president and director, formerly head of licensing activities for Ligand Pharmaceuticals Inc. WIR Staff autoimmune cancer Inflammation...
BioCentury | Apr 27, 1998
Company News

BBI Pharmaceuticals Inc. cancer news

...BBI changed its name to ProtoMed Inc. The company develops serine protease inhibitors derived from soybeans. BBI...
Items per page:
1 - 8 of 8